bioRxiv Science⌕ Search

Biology subjects

Engarimbi, J. E.

Publications and source records attributed to Engarimbi, J. E..

2 recordsLinked to original sources

Retrospective Computational and Immunoinformatics Validation of Clinically Evaluated Necator americanus Protein Vaccine Candidates: Na-APR-1, Na-GST-1, and Na-ASP-2

Hookworm disease, primarily caused by Necator americanus, affects about 472 million people worldwide and contributes substantially to global disease burden, yet no approved vaccine is currently available. The clinical failure of Na-ASP-2 protein due to IgE-mediated hypersensitivity highlights the need for safe, immunogenic hookworm vaccines and emphasizes the importance of rigorous pre-clinical safety screening. Using an integrated immunoinformatics approach, this work retrospectively evaluated the safety and immunogenicity of three clinical hookworm protein vaccine candidates: Na-APR-1, Na-GST-1, and Na-ASP-2. Toxigenicity and allergenicity predictions correctly identified Na-ASP-2 as toxigenic and allergenic, consistent with its documented clinical failure, while Na-APR-1 exhibited a favourable safety profile; Na-GST-1 showed inconsistent allergenicity signals warranting experimental validation. Comprehensive epitope prediction identified abundant CTL, HTL, B-cell, and cytokine-inducing epitopes across all candidates, with Na-APR-1 demonstrating the broadest epitope repertoire. HLA population coverage analysis indicated broad global applicability across endemic regions. Molecular docking with TLR4 revealed that all antigens interact with the receptor with binding energies more favourable than the positive control agonist, with Na-GST-1 and Na-APR-1 displaying the strongest predicted affinities. Normal mode analyses predicted stable antigen-TLR4 complex dynamics across all candidates. Immune simulations predicted robust, memory-driven humoral and cellular responses for Na-APR-1 and Na-ASP-2, while Na-GST-1 showed markedly attenuated simulated immunogenicity despite favourable structural and receptor-binding characteristics. These findings support continued clinical development of Na-APR-1, highlight unresolved immunogenic discordances for Na-GST-1 requiring experimental verification, and collectively provide a validated computational framework for advancing rational hookworm vaccine design.

immunology↗

In silico design and computational characterization of novel chimeric multiepitope antigens for Mpox serosurveillance

BackgroundThe Monkeypox (Mpox) virus is a zoonotic Orthopoxvirus with a global outbreak that began in 2022 and spread to more than 128 countries, with more than 132,000 confirmed cases and 1500 deaths. The pandemic preparedness pipeline emphasizes the importance of diagnostic surveillance of pathogens in at-risk populations to monitor transmission and mitigate the impact on public health. Unfortunately, the current gold standard diagnostic tool for Mpox is limited in its field applicability. Therefore, there is a crucial need for the development of robust novel diagnostic tools to enable continuous surveillance of the disease. As such, this work sought to design and validate novel multiepitope antigens as diagnostic tools for Mpox serosurveillance. MethodsUsing immunoinformatic approaches, two novel Mpox multiepitope antigens (MP-MEDA-1 and MP-MEDA-2) were designed using linear B-epitopes of viral proteins previously characterized in Mpox serodiagnosis. The 3D structures of the designed antigens were predicted, refined, and validated. Protein-protein docking and interaction analyses were performed between the designed diagnostic antigens and the Fab regions of human IgA, IgG, and IgM. ResultsThe designed antigens were predicted to be antigenic and demonstrated thermostability with desirable physicochemical properties. In addition, both antigens also demonstrated stable interactions with the Fab regions of selected immunoglobulins, with several residues interacting at the interfaces of all the docked complexes. ConclusionsThese preliminary findings highlight the potential of the MP-MEDA-1 and MP-MEDA-2 antigens as candidates to be further characterized for Mpox serosurveillance. The next phase of this project will focus on the expression and serological characterization of both antigens to determine their diagnostic parameters (sensitivity, specificity, and others).

immunology↗